Loading...

Media is loading
 

Date of Award

Spring 2020

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Amanda Seymour

Abstract

Chronic kidney disease (CKD) is a progressive disease process

that leads to a decline in kidney function and eventual kidney

failure. One of the leading causes of CKD is type 2 diabetes.

Novel diabetic agents have been developed and have shown

promise in slowing the progression of CKD in patients with type

2 diabetes. The purpose of this review was to compare SGLT-2

inhibitors (I) and GLP-1 receptor agonists (C) to determine their

impact on nephropathy indicators (O) in type 2 diabetic patients

with CKD (P).

Additional Files

EKaye - Capstone Poster Presentation.pdf (14115 kB)

Share

COinS
 

Comparison of two novel agents in slowing the progression of chronic kidney disease in patients with type 2 diabetes

Chronic kidney disease (CKD) is a progressive disease process

that leads to a decline in kidney function and eventual kidney

failure. One of the leading causes of CKD is type 2 diabetes.

Novel diabetic agents have been developed and have shown

promise in slowing the progression of CKD in patients with type

2 diabetes. The purpose of this review was to compare SGLT-2

inhibitors (I) and GLP-1 receptor agonists (C) to determine their

impact on nephropathy indicators (O) in type 2 diabetic patients

with CKD (P).